Table 2.
Agents used to prevent and treat influenza: M2 inhibitors (22)
| Drug | Suggested dosage | Usual adult dosage1 | Dose adjustment state | |
|---|---|---|---|---|
| Prophylaxis | Treatment | |||
| Amantadine | 100 mg b.i.d. | 100 mg b.i.d. | ||
| 5 mg/kg to max of 150 mg in two divided doses | Age 1–9 years | |||
| 100 mg q.o.d. | CrCl 30–50 mL/min | |||
| 100 mg q.o.d. | CrCl 15—30 mL/min | |||
| 100 mg q. week | CrCl 10—15 mL/min | |||
| 100 mg q week | CrCl,10 mL/min | |||
| 100 mg q.o.d. | Age ≥65 years | |||
| Rimantadine | 100 mg b.i.d. | 100 mg b.i.d. | ||
| 5 mg/kg to max of 150 mg in two divided doses | Age 1–9 years2 | |||
| 100 mg q.o.d. | CrCl,10 mL/min | |||
| 100 mg q.o.d. | Severe hepatic dysfunction | |||
| 100 mg q.o.d. | Age ≥65 years | |||
1Duration of treatment is usually 5 days. Duration of prophylaxis depends of the clinical setting.
2Investigational: Not approved for treatment of children by the US Food and Drug Administration and Health Canada.